Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESTORE: Clemastine for remyelination in internuclear ophthalmoparesis and multiple sclerosis
2024-513099-17-00Phase 3Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of clemastine in multiple sclerosis (MS) and internuclear ophthalmoplegia (INO) (2 arms), sponsored by Amsterdam University Medical Center. Started Aug 2024; status: completed.
02
Drugs
clemastine
03
Conditions
multiple sclerosis (MS)internuclear ophthalmoplegia (INO)
Beyond the preview
Go deeper on 2024-513099-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513099-17-00.